Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection.
Yang
Darice
D
Arkfeld
Daniel
D
Fong
Tse-Ling
TL
D018501:Antirheumatic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood; D004337:Drug Carriers / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D007596:Joints / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D000998:Antiviral Agents; D001323:Autoantibodies; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010456:Peptides, Cyclic; D011994:Recombinant Proteins; C487763:cyclic citrullinated peptide; D011092:Polyethylene Glycols; D012460:Sulfasalazine; D006886:Hydroxychloroquine; C100416:peginterferon alfa-2a